Media Wave Converges on Unapproved Peptide Injections — WSJ, SciAm, FT

The Wall Street Journal, Scientific American, the Financial Times, and The Conversation each published overlapping investigations or analyses of unapproved peptide injections within a single week — a concentration of mainstream media attention that industry observers say represents a turning point in how the peptide regulatory debate is framed for the general public.

The Wall Street Journal (paywall) published an investigation headlined “The Explosive Rise of Unapproved Peptide Injections” on May 7, examining the growing popularity of unregulated peptide therapies among wellness enthusiasts, athletes, and longevity-seekers and the associated health risks. The piece ran on the Journal’s health and wellness section, reaching a business-oriented readership that overlaps with the investor class funding peptide startups.

On May 8, Scientific American published “The truth about peptides that social media won’t tell you,” a science-driven examination of the gap between the enthusiastic online claims about peptides and the available clinical evidence. The piece adds scientific credibility to the media wave, reaching an audience that relies on evidence-based reporting.

“These publications do not cover the same stories by accident,” said a media analyst who tracks health policy coverage. “When the WSJ, SciAm, the FT, and The Conversation all train their attention on the same emerging issue within days of each other, it signals that the topic has reached a critical mass of public interest and policy relevance.”

Novo Nordisk CEO invokes ‘peptide craze’

The Financial Times (paywall) reported on May 6 that Novo Nordisk executives attributed rising sales of the company’s newly approved Wegovy (oral semaglutide) pill in part to what they called the “US peptide craze.” It is the first known instance of a major pharmaceutical company’s leadership publicly describing the market using that term, linking the blockbuster GLP-1 drug category to the broader unapproved peptide injection trend.

The Financial Times report noted that Novo Nordisk’s oral Wegovy formulation, which received FDA approval in December 2025, has benefited from increased public awareness of peptides as a therapeutic category — even as the company’s FDA-approved products remain sharply distinct from the unapproved injectable peptides promoted by wellness influencers.

The Conversation adds academic perspective

The Conversation, an academic journalism platform, published “Can peptide injections help people recover from injuries? Here’s what you need to know” on May 7, providing a research-informed perspective on the evidence (or lack thereof) supporting BPC-157, TB-500, and related peptides for musculoskeletal recovery. The piece was syndicated to Medical Xpress and local news outlets nationwide.

Media wave builds ahead of July PCAC

The cluster of coverage arrives as the FDA prepares for a July 2026 meeting of the Pharmacy Compounding Advisory Committee (PCAC), which will review whether seven peptide therapies — including BPC-157, TB-500, and several others — should remain on the FDA’s Category 2 list of substances that present significant safety concerns when compounded.

The FDA’s April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk substances list has further intensified public and press interest in the compounding and peptide policy space. PeptidesBeat reported that the agency’s GLP-1 decision uses the same clinical-need standard that will govern peptide compounding after PCAC.

Dr. Peter Lurie, a former FDA associate commissioner who now leads the Center for Science in the Public Interest, told the Associated Press in an April 15 report syndicated by PBS that allowing peptides on the market without clinical testing poses a “profound risk to the public health.”

Venture capital flows despite regulatory uncertainty

The week’s positive coverage also included Axios’s May 4 report that a former Coatue Management general partner raised $16 million for a peptide-focused startup — indicating that private investment in the space continues despite or perhaps because of the regulatory uncertainty surrounding FDA’s July PCAC decision.

The combination of regulatory action (the GLP-1 503B proposal), an upcoming advisory committee meeting (July PCAC), venture capital interest, and coordinated mainstream media attention — following earlier coverage of the hype-versus-evidence gap — suggests the peptide policy debate is entering a new phase — one in which public awareness and investor expectations are rising in parallel with regulatory stakes.

What to watch

Market observers and policy analysts will be tracking:

• July PCAC meeting: The FDA advisory committee’s recommendations on seven peptide bulk substances could reshape the compounding landscape.
• FDA GLP-1 503B rulemaking: The comment period on the agency’s proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list runs through June 29.
• Next wave of coverage: Whether additional major outlets — including Time, The New York Times, or The Atlantic — follow the WSJ and SciAm with their own investigations. On May 13, The Times of London published a deep feature on the peptide injectables industry, joined by Oprah Daily and the Globe and Mail, confirming a third wave of global mainstream coverage.
• International regulatory response: The Australian TGA’s May 11 warning on illegal peptide use and border seizures added a global dimension, with the U.K.\u2019s MHRA and European regulators also issuing parallel alerts.\n- Legislative activity: Congressional interest in peptide policy, including letters from Sen. Tommy Tuberville (R-AL) and others urging the FDA to loosen restrictions.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.